Publications by authors named "C Delavaud"
Article Synopsis
- Low-grade oncocytic tumor (LOT) is a rare type of kidney tumor that resembles other renal tumors, making it hard to diagnose; this study aimed to better understand its imaging characteristics.* -
- Researchers analyzed preoperative imaging from 12 confirmed LOT cases using CT or MRI, finding common features such as well-defined borders and specific patterns of enhancement.* -
- The study concludes that certain imaging features can suggest LOT, but further research is needed for validation, and a biopsy is recommended before treatment decisions.*
Background: The overall cancer risk increases in transplant patients, including in kidney allografts. This study aimed to analyze the outcome of patients with kidney allograft malignant tumors who underwent percutaneous thermal ablation.
Methods: We included 26 renal allograft tumors, including 7 clear-cell renal cell carcinoma (RCCs), 16 papillary RCCs, 1 clear-cell papillary RCC, and 2 tubulocystic RCCs, treated in 19 ablation sessions.
Article Synopsis
- - The study focuses on continuous and deep sedation maintained until death (CDSUD) in palliative care, especially for patients experiencing refractory suffering or who request to stop life-sustaining treatment.
- - A retrospective analysis of 42 hospitalized patients showed that 79% initiated CDSUD due to persistent suffering, with midazolam as the primary sedative, often combined with chlorpromazine and propofol.
- - Findings reveal an average sedation duration of 37 hours, with specific dosages for each sedative, contributing valuable insights into CDSUD practices in palliative care settings.
Objectives: Contrast enhancement by MRI done early after cryoablation for renal malignancies may suggest residual tumor (RT). However, we have observed MRI enhancement within 48 h of cryoablation in patients who had no contrast enhancement 6 weeks later. Our purpose was to identify features of 48-h contrast enhancement in patients without RT.
View Article and Find Full Text PDFArticle Synopsis
- - Managing malignant renal tumors requires careful consideration of treatment necessity, factoring in the patient's renal function, risk of chronic kidney disease, and overall survival chances.
- - Treatment choices vary, focusing on tumor size, location, and the patient's health status, with an emphasis on renal-sparing techniques for small tumors.
- - Effective management relies on collaboration among urologists, radiologists, nephrologists, and sometimes radiotherapists to provide optimal care.